Heart Failure With Normal Ejection FractionNCT03672591
Renal Hemodynamics in Patients With HFpEF
An observational study of Heart Failure With Normal Ejection Fraction, run by University of Erlangen-Nürnberg Medical School at 2 sites in Germany.
Trial summary
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality. The relationship between HFpEF and renal impairment is bidirectional. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Heart Failure With Normal Ejection Fraction
- What is being tested?
- Renal clearance examination
- Type of treatment
- Injection or infusion
- How many people
- 40 participants
- Where
- 2 sitesGermany
- Study dates
- 30 Nov 2018to 30 Jun 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: HFpEF patients: recruitment from the investigator's outpatient clinics and referring physicians. Control subjects without HFpEF: individuals who already participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)
Who may be able to join
- Patients in good and stable health condition
- Informed consent has to be given in written form
- HFpEF in stable conditions according to 2016 ESC guidelines definition14
- LVEF ≥ 50%
- symptoms and/or signs of CHF
- NT-proBNP > 125 pg/ml
- At least one additional criterion: relevant structural heart disease (left ventricular hypertrophy and/or left atrial enlargement and/or diastolic dysfunction
Who cannot join
- Uncontrolled diabetes (fasting plasma glucose ≥ 240 mg/dl, HbA1c ≥ 10%)
- Uncontrolled arterial hypertension (≥ 180/110 mmHg)
- Any history of stroke, transient ischemic attack, instable angina pectoris or myocardial infarction within the last 6 months prior to study inclusion
- Significant valvular heart disease
- Known hypertrophic obstructive cardiomyopathy or known pericardial constriction
- Atrial fibrillation with a resting heart rate > 90 bpm
Show all 25Show fewer
- Heart transplant recipient
- Sickle cell anemia
- Pheochromocytoma
- Myasthenia gravis
- Subclinical or clinical hyperthyroidism
- Allergic reaction to iodine
- Medication with amiodarone
- Estimated glomerular filtration rate < 30 ml/min/1.73m²
- Significant laboratory abnormalities such as Serum Glutamate-Oxaloacetate-Transaminase (SGOT) or Serum Glutamate-Pyruvate-Transaminase (SGPT) levels more than 3 times above the upper limit of normal range
- Patients in unstable conditions due to any kind of serious disease, that infers with the conduction of the trial
- History of epilepsia and history of seizures
- Patients suffering from cataract or glaucoma
- Diabetic retinopathy
- Drug or alcohol abuse
- Pregnant and breast-feeding patients
- Body mass index > 40 kg/m²
- Participation in another clinical study within 30 days prior to visit 1
- Individuals at risk for poor protocol adherence
- Subjects who do not give written consent, that pseudonymous data will be transferred in line with the duty of documentation and the duty of notification according to § 12 and § 13 GCP-V
Trial locations and contacts
2 sites in 1 country.
Germany2 sites
Clinical Research Center Erlangen, Department of Nephrology and Hypertension, University Hospital Erlangen
Erlangen
Clinical Research Center Nuremberg, Department of Nephrology, University Hospital Erlangen
Nuremberg
About this study
Official title: Cross-sectional Observational Single-center Study to Evaluate Renal Hemodynamics in Patients With Heart Failure and Preserved Ejection Fraction
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality. The relationship between HFpEF and renal impairment is bidirectional. On the one hand, renal dysfunction has been shown to be an independent risk factor for the development of HFpEF. On the other hand, an increase in central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF) and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone system (RAAS) in patients with HFpEF has been previously described.
In the literature, several studies aimed to investigate the association between renal (dys-) function and HFpEF. In all these studies, renal function was assessed by determination of standard kidney function parameters such as serum creatinine, eGFR and urinary albumin to creatinine ratio (UACR). Constant infusion input clearance technique however offers a more detailed evaluation of renal function and hemodynamics. To the best of knowledge, renal hemodynamics in patients with HFpEF have not yet been investigated by clearance technique. Therefore, the aim of the present study is to evaluate renal function and hemodynamics by means of constant infusion input clearance technique with sodium p-aminohippuric acid (PAH) and Iohexol in 40 patients with HFpEF. The constant infusion input clearance technique offers an exact evaluation of renal function by measuring (not estimating) glomerular filtration rate and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction (FF) and intraglomerular pressure (IGP). These results will be compared to 140 subjects without HFpEF that have participated in various studies and have been analyzed with the same constant infusion input clearance technique performed in the Clinical Research Center of the University Hospital Erlangen-Nuremberg. Additionally, flow mediated vasodilation (FMD), pulse wave velocity and parameters of retinal vascular remodeling by means of scanning laser Doppler flowmetry (SLDF) will be assessed in patients with HFpEF thereby allowing to examine the relationship between vascular remodeling in the systemic and renal circulation.
Read the detailed description
Several studies evaluating the outcome among patients with HFpEF revealed that this entity of heart failure (HF) is associated with high mortality rates and some studies even indicate that mortality is similar to patients with heart failure and reduced ejection fraction (HFrEF). Hospitalization for HFpEF is increasing relative to HFrEF, highlighting the need for a better understanding of the pathogenetic processes in order to develop new treatment strategies for this type of HF. Recently, the PARAMOUNT study revealed that in patients with HFpEF, treatment with the dual-acting angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 was associated with lower levels of creatinine and higher estimated glomerular filtration rates (eGFR) indicating a better preservation of renal function in comparison to treatment with valsartan only. Another observation of this study was an increase in urinary albumin to creatinine ratio (UACR) in the group of LCZ696-treatment, which was not visible in patients randomized to the valsartan group. Additionally, analysis of the relation between albuminuria and/or decreased eGFR and cardiovascular function and structure revealed that renal dysfunction was common in this group of patients and associated with cardiac remodeling and dysfunction.
Up to two thirds of patients with HFpEF are suffering from chronic kidney disease (CKD). A bidirectional cardiorenal relation has been recently described and is known to be associated with adverse cardiovascular outcome and increased mortality. On the one hand, renal dysfunction has been shown to be an independent risk factor for the development of HFpEF due to inflammatory processes and endothelial dysfunction. On the other hand, an increase in central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF) and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone system (RAAS) in patients with HFpEF has been previously described.
This association has also been demonstrated for patients with HFrEF. However, several studies comparing patients with the two subtypes of HF in the context of CKD indicate that this association is more pronounced in patients with HFpEF. For example, a community-based cohort study by Brouwers et al. including 8592 subjects of the PREVEND trial showed that renal function parameters such as urinary albumin excretion (UAE) and cystatin C were associated with a high risk for the development of HFpEF but not HFrEF. Ahmed et al. even reported a higher CKD-related mortality in HFpEF than in HFrEF patients with an underlying graded-response relation as CKD-associated mortality increased with higher left ventricular ejection fraction (LVEF). These findings suggest different pathogenetic processes for these two subtypes of HF. Therefore, detailed exploration of the pathophysiological mechanisms behind the relationship of HFpEF and renal function represents a matter of major research interest.
Recently, several studies aimed to investigate the association between renal (dys-) function and HFpEF. Unger et al. retrospectively examined the relationship between renal function and echocardiographic parameters in 299 patients with HFpEF. The analysis revealed that CKD was independently associated with worse cardiac mechanics and outcomes in this population.9 Studying 217 participants from the PARAMOUNT trial with HFpEF, Gori et al. demonstrated that renal dysfunction was associated with abnormal left ventricular geometry, lower midwall fractional shortening and higher NT-proBNP. In both studies, renal function was assessed with commonly used tests such as determination of serum creatinine, eGFR and urinary albumin to creatinine ratio (UACR). However, these parameters only allow an approximate estimation of renal function. Constant infusion input clearance technique offers a more complete approach towards evaluation of renal function and perfusion, allowing an exact quantification of glomerular filtration rate (GFR) and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction (FF) and intraglomerular hemodynamics.
The definition of HFpEF in literature is rather inconsistent. In some studies, HFpEF was defined by an ejection fraction of ≥ 45%, whereas other authors used a cut-off value of 50%. In the present study, the categorization of heart failure as HFpEF will follow the 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure applying a cut-off value of 50%.
The purpose of the present study is to evaluate renal function and hemodynamics by means of constant infusion input clearance technique with PAH and Iohexol in 40 patients with HFpEF with the aim to better characterize the relationship between renal dysfunction and HFpEF. These results will be compared to 140 subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in the Clinical Research Center of the University Hospital Erlangen-Nuremberg. In parallel, pulse wave velocity, flow mediated vasodilation and other vascular parameters, reflecting the vascular wall properties of small and large arteries, will be assessed. Additionally, there will be a non-invasive retinal examination to assess vascular remodeling of retinal arterioles (wall to lumen ratio, WLR), retinal capillary flow (RCF) and capillary rarefaction.
- Being tested
- Renal clearance examination
- Keywords
- Heart failure, Renal clearance technique, Preserved ejection fraction
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Renal clearance examinationOther
Also called Scanning laser Doppler flowmetry, SphygmoCor, UnexEF
Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
| Study group | Role | What they receive |
|---|---|---|
| HFpEF patients | Patients suffering from heart failure with preserved ejection fraction Receives: Other: Renal clearance examination | |
| Control group | Subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745) Receives: Other: Renal clearance examination |
What is being measured
The primary outcome is the main question the study is designed to answer.
Renal plasma flow
Volume of blood plasma delivered to the kidneys per unit time (ml/min)
Measured: One week after study inclusion
Secondary outcomes (11)
Flow mediated vasodilation
Measured by UNEX EF in percent
Measured: One week after study inclusion
Wall to lumen ratio of retinal arterioles
ratio of vascular wall thickness to luminal diameter
Measured: One week after study inclusion
Retinal capillary flow
by SLDF measurement in AU
Measured: One week after study inclusion
Office and 24-hour systolic, diastolic and mean ambulatory blood pressure
in mmHg
Measured: One week after study inclusion
Central systolic pressure
measured by SphygmoCor in mmHg
Measured: One week after study inclusion
Pulse pressure
difference between systolic and diastolic blood pressure in mmHg
Measured: One week after study inclusion
Pulse wave velocity
velocity at which the blood pressure pulse propagates through the circulatory System measured by SphygmoCor in m/s
Measured: One week after study inclusion
Glomerular filtration rate
Flow rate of filtered fluid through the kidney in ml/min/1.73m^2
Measured: One week after study inclusion
Filtration fraction
Ratio of glomerular filtration rate to renal plasma flow in percent
Measured: One week after study inclusion
Renal vascular resistance
Calculated by the Gomez formula in dyn x sec x cm^-5
Measured: One week after study inclusion
Intraglomerular pressure
in mmHg
Measured: One week after study inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2018
- Study start30 Nov 2018
- Primary completion30 Jun 2019
- Study completion30 Jun 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Heart Failure With Normal Ejection FractionStudies of the same condition, open and under way.
- More trials run by University of Erlangen-Nürnberg Medical SchoolThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Roland E. Schmieder, University of Erlangen-Nürnberg Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03672591
- Sponsor's protocol ID
- CRC2018HFpEF
- Status last verified
- Jul 2019
- First submitted
- 4 Sep 2018
- Last updated
- 10 Jul 2019
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Jung S, Bosch A, Kolwelter J, Striepe K, Kannenkeril D, Schuster T, Ott C, Achenbach S, Schmieder RE. Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2021 Apr;8(2):1562-1570. doi: 10.1002/ehf2.13257. Epub 2021 Feb 9.
PubMed 33559346
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cross-sectional Observational Single-center Study to Evaluate Renal Hemodynamics in Patients With Heart Failure and Preserved Ejection Fraction
- ClinicalTrials.gov ID
- NCT03672591
- Acronym / sponsor ID
- CRC2018HFpEF
- Keywords
- Heart failure, Renal clearance technique, Preserved ejection fraction
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University of Erlangen-Nürnberg Medical SchoolUniversity, hospital or other
- Study start
- 30 Nov 2018 (actual)
- Primary completion
- 30 Jun 2019 (actual)
- Study completion
- 30 Jun 2019 (actual)
- First posted
- 14 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality. The relationship between HFpEF and renal impairment is bidirectional. On the one hand, renal dysfunction has been shown to be an independent risk factor for the development of HFpEF. On the other hand, an increase in central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF) and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone system (RAAS) in patients with HFpEF has been previously described.
In the literature, several studies aimed to investigate the association between renal (dys-) function and HFpEF. In all these studies, renal function was assessed by determination of standard kidney function parameters such as serum creatinine, eGFR and urinary albumin to creatinine ratio (UACR). Constant infusion input clearance technique however offers a more detailed evaluation of renal function and hemodynamics. To the best of knowledge, renal hemodynamics in patients with HFpEF have not yet been investigated by clearance technique. Therefore, the aim of the present study is to evaluate renal function and hemodynamics by means of constant infusion input clearance technique with sodium p-aminohippuric acid (PAH) and Iohexol in 40 patients with HFpEF. The constant infusion input clearance technique offers an exact evaluation of renal function by measuring (not estimating) glomerular filtration rate and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction (FF) and intraglomerular pressure (IGP). These results will be compared to 140 subjects without HFpEF that have participated in various studies and have been analyzed with the same constant infusion input clearance technique performed in the Clinical Research Center of the University Hospital Erlangen-Nuremberg. Additionally, flow mediated vasodilation (FMD), pulse wave velocity and parameters of retinal vascular remodeling by means of scanning laser Doppler flowmetry (SLDF) will be assessed in patients with HFpEF thereby allowing to examine the relationship between vascular remodeling in the systemic and renal circulation.
Detailed description
Several studies evaluating the outcome among patients with HFpEF revealed that this entity of heart failure (HF) is associated with high mortality rates and some studies even indicate that mortality is similar to patients with heart failure and reduced ejection fraction (HFrEF). Hospitalization for HFpEF is increasing relative to HFrEF, highlighting the need for a better understanding of the pathogenetic processes in order to develop new treatment strategies for this type of HF. Recently, the PARAMOUNT study revealed that in patients with HFpEF, treatment with the dual-acting angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 was associated with lower levels of creatinine and higher estimated glomerular filtration rates (eGFR) indicating a better preservation of renal function in comparison to treatment with valsartan only. Another observation of this study was an increase in urinary albumin to creatinine ratio (UACR) in the group of LCZ696-treatment, which was not visible in patients randomized to the valsartan group. Additionally, analysis of the relation between albuminuria and/or decreased eGFR and cardiovascular function and structure revealed that renal dysfunction was common in this group of patients and associated with cardiac remodeling and dysfunction.
Up to two thirds of patients with HFpEF are suffering from chronic kidney disease (CKD). A bidirectional cardiorenal relation has been recently described and is known to be associated with adverse cardiovascular outcome and increased mortality. On the one hand, renal dysfunction has been shown to be an independent risk factor for the development of HFpEF due to inflammatory processes and endothelial dysfunction. On the other hand, an increase in central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF) and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone system (RAAS) in patients with HFpEF has been previously described.
This association has also been demonstrated for patients with HFrEF. However, several studies comparing patients with the two subtypes of HF in the context of CKD indicate that this association is more pronounced in patients with HFpEF. For example, a community-based cohort study by Brouwers et al. including 8592 subjects of the PREVEND trial showed that renal function parameters such as urinary albumin excretion (UAE) and cystatin C were associated with a high risk for the development of HFpEF but not HFrEF. Ahmed et al. even reported a higher CKD-related mortality in HFpEF than in HFrEF patients with an underlying graded-response relation as CKD-associated mortality increased with higher left ventricular ejection fraction (LVEF). These findings suggest different pathogenetic processes for these two subtypes of HF. Therefore, detailed exploration of the pathophysiological mechanisms behind the relationship of HFpEF and renal function represents a matter of major research interest.
Recently, several studies aimed to investigate the association between renal (dys-) function and HFpEF. Unger et al. retrospectively examined the relationship between renal function and echocardiographic parameters in 299 patients with HFpEF. The analysis revealed that CKD was independently associated with worse cardiac mechanics and outcomes in this population.9 Studying 217 participants from the PARAMOUNT trial with HFpEF, Gori et al. demonstrated that renal dysfunction was associated with abnormal left ventricular geometry, lower midwall fractional shortening and higher NT-proBNP. In both studies, renal function was assessed with commonly used tests such as determination of serum creatinine, eGFR and urinary albumin to creatinine ratio (UACR). However, these parameters only allow an approximate estimation of renal function. Constant infusion input clearance technique offers a more complete approach towards evaluation of renal function and perfusion, allowing an exact quantification of glomerular filtration rate (GFR) and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction (FF) and intraglomerular hemodynamics.
The definition of HFpEF in literature is rather inconsistent. In some studies, HFpEF was defined by an ejection fraction of ≥ 45%, whereas other authors used a cut-off value of 50%. In the present study, the categorization of heart failure as HFpEF will follow the 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure applying a cut-off value of 50%.
The purpose of the present study is to evaluate renal function and hemodynamics by means of constant infusion input clearance technique with PAH and Iohexol in 40 patients with HFpEF with the aim to better characterize the relationship between renal dysfunction and HFpEF. These results will be compared to 140 subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in the Clinical Research Center of the University Hospital Erlangen-Nuremberg. In parallel, pulse wave velocity, flow mediated vasodilation and other vascular parameters, reflecting the vascular wall properties of small and large arteries, will be assessed. Additionally, there will be a non-invasive retinal examination to assess vascular remodeling of retinal arterioles (wall to lumen ratio, WLR), retinal capillary flow (RCF) and capillary rarefaction.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HFpEF patients | – | Other: Renal clearance examinationPatients suffering from heart failure with preserved ejection fraction |
| Control group | – | Other: Renal clearance examinationSubjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745) |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- HFpEF patients: recruitment from the investigator's outpatient clinics and referring physicians. Control subjects without HFpEF: individuals who already participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)
Key inclusion criteria (7 listed)
- Patients in good and stable health condition
- Informed consent has to be given in written form
- HFpEF in stable conditions according to 2016 ESC guidelines definition14
Key exclusion criteria (25 listed)
- Uncontrolled diabetes (fasting plasma glucose ≥ 240 mg/dl, HbA1c ≥ 10%)
- Uncontrolled arterial hypertension (≥ 180/110 mmHg)
- Any history of stroke, transient ischemic attack, instable angina pectoris or myocardial infarction within the last 6 months prior to study inclusion
- Significant valvular heart disease
- Known hypertrophic obstructive cardiomyopathy or known pericardial constriction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Renal clearance examinationAlso: Scanning laser Doppler flowmetry, SphygmoCor, UnexEFEvaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol | Other | Control group, HFpEF patients |
Primary outcome
Renal plasma flow
Time frame: One week after study inclusion
Volume of blood plasma delivered to the kidneys per unit time (ml/min)
11 secondary outcomes
Flow mediated vasodilation
Time frame: One week after study inclusion
Wall to lumen ratio of retinal arterioles
Time frame: One week after study inclusion
Retinal capillary flow
Time frame: One week after study inclusion
Office and 24-hour systolic, diastolic and mean ambulatory blood pressure
Time frame: One week after study inclusion
Central systolic pressure
Time frame: One week after study inclusion
Pulse pressure
Time frame: One week after study inclusion
Pulse wave velocity
Time frame: One week after study inclusion
Glomerular filtration rate
Time frame: One week after study inclusion
Filtration fraction
Time frame: One week after study inclusion
Renal vascular resistance
Time frame: One week after study inclusion
Intraglomerular pressure
Time frame: One week after study inclusion
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2019.
- Derived from this study: PubMed 33559346Jung S, Bosch A, Kolwelter J, Striepe K, Kannenkeril D, Schuster T, Ott C, Achenbach S, Schmieder RE. Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2021 Apr;8(2):1562-1570. doi: 10.1002/ehf2.13257. Epub 2021 Feb 9.
- Individual participant dataSharing planned: Undecided
Related trials for Heart Failure With Normal Ejection Fraction
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
RecruitingPhase 2
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
HFpEF - Heart Failure With Preserved Ejection Fraction
RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Recruiting
PrEcision Pacing in HFpEF: the PEP-HFpEF Trial
Heart Failure and Preserved Ejection Fraction, Heart Failure New York Heart Association Class III
Active, not recruiting
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure With Normal Ejection Fraction, run by University of Erlangen-Nürnberg Medical School at 2 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Renal plasma flow (time frame: One week after study inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03672591, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2019.